Latest news with #RRP
National Post
27-05-2025
- Business
- National Post
JT Group Launches Ploom AURA and EVO Heated Tobacco Sticks in Japan
Article content Article content TOKYO — Japan Tobacco Inc. (JT)(TSE:2914) launches Ploom AURA, its next generation heated tobacco device, on May 27, 2025, in Japan, primarily in its Ploom stores and CLUB JT online shop. In parallel, JT Group will roll out EVO, its exclusive and premium heated tobacco sticks (HTS), to complement Ploom AURA and provide adult consumers with the latest and most technologically advanced propositions in the heated tobacco segment. A nationwide launch of Ploom AURA and EVO will start on July 1 in convenience stores and tobacco retail shops. Ploom AURA will roll out globally in the near future. Article content The purpose of JT Group's tobacco business is: Creating fulfilling moments. Creating a better future. And with the launch of Ploom AURA in Japan, the world's leading heated tobacco market, JT Group is taking further steps in this direction – bringing to market and adult consumers an innovative and state-of-the-art heated tobacco device, following extensive consumer insights as well as strong research and development. Article content 'In the Reduced-Risk Products (RRP)* category, we are focusing on providing adult consumers with quality products, rooted in technology, consumer insights, and experience and I truly believe Ploom AURA embraces all these aspects and more. The JT Group will continue to prioritize investments in the heated tobacco sticks segment which maintains the strongest and most consistent growth in the RRP space. Over the course of 2025-2027, we are investing 650 billion yen in RRP, and a significant part of this will be towards Ploom AURA, notably on the launch in Japan and globally,' said Takehiko Tsutsui, Executive Vice President of Reduced-Risk Products. Article content Ploom AURA's key focus is on enhancing flavor and the device leverages SMART HEATFLOW heating technology, delivering sensory satisfaction while enabling consumers to enjoy the full essence and richness of tobacco with the absence of combustion and no smell of smoke. The new Heat Select System offers four modes for users to customize their experience in line with their preferences. The device maintains the delicate and organic curves characteristic of Ploom, while evolving into a compact and slim design – combining elegance and practicality. Article content EVO is JT Group's global heated tobacco sticks brand, designed to seamlessly enhance Ploom's advanced heating technology and reduced-risk potential. EVO sticks are made from high-quality tobacco leaves, expertly cut and blended to provide a true tobacco taste. An example of meticulous attention to detail, EVO guarantees a satisfying experience with every puff. Article content The combination of the cutting-edge technology of Ploom AURA, along with the high-quality EVO heated tobacco sticks, will ensure consumers consistently experience pleasurable heated tobacco moments. Article content 'The RRP category is reshaping the global tobacco landscape, and I am confident that Ploom AURA and EVO will play key roles in supporting JT Group's ambition of reaching mid-teens share in the HTS segment by 2028,' added Tsutsui. Article content *Reduced-Risk Products (RRP): Products with the potential to reduce the risks associated with smoking, such as Heated Tobacco Products, E-Vapor (or vapes), and Oral products like nicotine pouches. Article content Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand. Article content Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its 'Fulfilling Moments, Enriching Life' purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit Article content Article content Article content Article content Article content Contacts Article content Investor and Media Relations Division Japan Tobacco Inc. Article content Article content Article content
Yahoo
27-05-2025
- Business
- Yahoo
JT Group Launches Ploom AURA and EVO Heated Tobacco Sticks in Japan
Its latest and most technologically advanced propositions in the Heated Tobacco Segment TOKYO, May 27, 2025--(BUSINESS WIRE)--Japan Tobacco Inc. (JT)(TSE:2914) launches Ploom AURA, its next generation heated tobacco device, on May 27, 2025, in Japan, primarily in its Ploom stores and CLUB JT online shop. In parallel, JT Group will roll out EVO, its exclusive and premium heated tobacco sticks (HTS), to complement Ploom AURA and provide adult consumers with the latest and most technologically advanced propositions in the heated tobacco segment. A nationwide launch of Ploom AURA and EVO will start on July 1 in convenience stores and tobacco retail shops. Ploom AURA will roll out globally in the near future. The purpose of JT Group's tobacco business is: Creating fulfilling moments. Creating a better future. And with the launch of Ploom AURA in Japan, the world's leading heated tobacco market, JT Group is taking further steps in this direction – bringing to market and adult consumers an innovative and state-of-the-art heated tobacco device, following extensive consumer insights as well as strong research and development. "In the Reduced-Risk Products (RRP)* category, we are focusing on providing adult consumers with quality products, rooted in technology, consumer insights, and experience and I truly believe Ploom AURA embraces all these aspects and more. The JT Group will continue to prioritize investments in the heated tobacco sticks segment which maintains the strongest and most consistent growth in the RRP space. Over the course of 2025-2027, we are investing 650 billion yen in RRP, and a significant part of this will be towards Ploom AURA, notably on the launch in Japan and globally," said Takehiko Tsutsui, Executive Vice President of Reduced-Risk Products. Ploom AURA's key focus is on enhancing flavor and the device leverages SMART HEATFLOW heating technology, delivering sensory satisfaction while enabling consumers to enjoy the full essence and richness of tobacco with the absence of combustion and no smell of smoke. The new Heat Select System offers four modes for users to customize their experience in line with their preferences. The device maintains the delicate and organic curves characteristic of Ploom, while evolving into a compact and slim design – combining elegance and practicality. EVO is JT Group's global heated tobacco sticks brand, designed to seamlessly enhance Ploom's advanced heating technology and reduced-risk potential. EVO sticks are made from high-quality tobacco leaves, expertly cut and blended to provide a true tobacco taste. An example of meticulous attention to detail, EVO guarantees a satisfying experience with every puff. The combination of the cutting-edge technology of Ploom AURA, along with the high-quality EVO heated tobacco sticks, will ensure consumers consistently experience pleasurable heated tobacco moments. "The RRP category is reshaping the global tobacco landscape, and I am confident that Ploom AURA and EVO will play key roles in supporting JT Group's ambition of reaching mid-teens share in the HTS segment by 2028," added Tsutsui. *Reduced-Risk Products (RRP): Products with the potential to reduce the risks associated with smoking, such as Heated Tobacco Products, E-Vapor (or vapes), and Oral products like nicotine pouches. Japan Tobacco Inc. (JT) is a global company headquartered in Tokyo, Japan. It is listed on the primary section of the Tokyo Stock Exchange (ticker: 2914.T). JT Group has approximately 53,000 employees and 62 factories worldwide, operating in three business segments: tobacco, pharmaceutical, and processed food. Within the tobacco business, the largest segment, products are sold in over 130 markets and its flagship brands include Winston, Camel, MEVIUS, and LD. The Group is committed to investing in Reduced-Risk Products and markets its heated tobacco products under its Ploom brand. Consumers, shareholders, employees, and society are the four stakeholder groups (4S) at the heart of all of JT Group's activities. Inspired by its "Fulfilling Moments, Enriching Life" purpose, the Group aims to ensure sustainable and valuable contributions to its stakeholders over the long term. In addition to our three business segments, this goal is also supported by D-LAB, the JT Group's corporate R&D initiative, set up to search and create added-value business opportunities. For more information, visit View source version on Contacts Investor and Media Relations DivisionJapan Tobacco InvestorsJerome Jaffeux, Head of IR: For MediaYunosuke Miyata, Director: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
&w=3840&q=100)
First Post
26-05-2025
- Entertainment
- First Post
Chinese drill photo as Op Bunyan memento: Pak PM's gift to army chief leaves netizens in splits
Asim Munir reportedly hosted a high-profile dinner last week, during which he presented the doctored image to political leaders as a token of appreciation for their 'foresight' during the four-day armed conflict with India read more Pakistan PM Shehbaz Sharif gifts Army Chief Asim Munir a framed image, falsely claiming it depicts Operation Bunyan al-Marsus against India—later exposed as a 2019 Chinese military drill. X In a further display of mockery, Pakistan Prime Minister Shehbaz Sharif presented Army Chief Asim Munir with a photo from a 2019 Chinese military exercise, falsely claiming it depicted Operation Bunyan al-Marsus against India. Netizens criticised both Pakistan's Prime Minister and Army Chief for the alleged use of Photoshop, and harshly condemned the move online. Asim Munir reportedly hosted a high-profile dinner last week, during which he presented the doctored image to political leaders as a token of appreciation for their 'foresight' during the four-day armed conflict with India. STORY CONTINUES BELOW THIS AD Indians mocked the gesture, accusing Pakistan of trying to 'win' the battle through Canva and Photoshop. Many shared the original image of the Chinese drill on X, drawing attention to the manipulation. One user said on X, 'Pakistan's latest masterpiece: Shehbaz Sharif presents a photoshopped painting from a 2019 Chinese drill to Failed Marshal Asim Munir. Guess when you can't win on the battlefield, you win in Canva.' Pakistan's latest masterpiece: Shehbaz Sharif presents a photoshopped painting from a 2019 Chinese drill to Failed Marshal Asim Munir 🎨💥 Guess when you can't win on the battlefield, you win in Canva #LumberOneFauj — Yash Rawat (@Yashfacts28) May 25, 2025 Another user asked,'Should we call it a country?' The comedian Asim Munir of Pakistan gifting painting of Operation Bunyan Al Marsus to another comedian PM Shahbaz Sharif during a dinner. It's actually a 2019 photo from a Chinese military exercise. 😛 Should we call it a country? #OperationSindoor — Rathan Ramesh Poojary (RRP)🇮🇳 (@RathanRameshRR1) May 25, 2025 STORY CONTINUES BELOW THIS AD 'Pakistan's PM gifts Asim Munir a 2019 Chinese drill photo, claiming it's 'OP Bunyan Al Marsus'. Pakistan is now using a Chinese Drill Photo to Celebrate Its own Military Operation. They can't even produce original visuals of their own military operation. Shehbaz Sharif and Asim Munir are fooling their entire Nation. REALLY,' said another user. BIG NEWS 🚨 Pakistan's PM gifts Asim Munir a 2019 Chinese drill photo, claiming it's 'OP Bunyan Al Marsus' 😭😂🔥 Pakistan is now using a Chinese Drill Photo to Celebrate Its own Military Operation 🤣 A high-profile dinner hosted by Pakistan Field Marshal Asim Munir, Chief of… — Times Algebra (@TimesAlgebraIND) May 26, 2025 STORY CONTINUES BELOW THIS AD
Yahoo
13-05-2025
- Business
- Yahoo
INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights
On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) in mid-2025 Device design verification (DV) testing of CELLECTRA device required for BLA submission is underway, anticipated completion in 1H25 Clinical and immunological results from Phase 1/2 trial of INO-3107 published in Nature Communications in February 2025 INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with significant clinical benefit as measured by reduced need for surgery Announced promising interim results from ongoing proof-of-concept Phase 1 trial showing DNA-encoded monoclonal antibodies (DMAbs) were well tolerated and exhibited long-lasting in vivo production Preprint manuscript available on PLYMOUTH MEETING, Pa., May 13, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the first quarter of 2025 and provided an update on recent company developments. "I'm pleased to confirm that we remain on track to submit our BLA for INO-3107 this year. As previously stated, our goal is to begin rolling submission in mid-2025, complete the submission in the second half of 2025 and receive file acceptance from the FDA by year end. If we receive priority review, it could allow for a PDUFA date in mid-2026," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "We continue to focus our efforts and resources toward bringing this important product candidate to patients eager for a non-surgical therapeutic option to treat this devastating disease. Based on market research, we believe INO-3107 could be the preferred product for patients and providers, if approved. Beyond INO-3107, we are excited about the recently announced promising data from a proof-of-concept Phase 1 clinical trial with our next-generation DMAb technology, as well as the potential of our entire DNA medicines pipeline." Operational Highlights INO-3107 – Recurrent Respiratory Papillomatosis (RRP)The DV testing for INO-3107 has been initiated and is anticipated to be completed in the first half of 2025. INOVIO plans to begin rolling submission of the BLA in mid-2025 under FDA's accelerated approval program, subject to FDA concurrence, with the goal of completing the submission in the second half of 2025 and receiving FDA acceptance of the submission by the end of the year. FDA has previously awarded breakthrough therapy designation for INO-3107 and INOVIO plans to request priority review of its BLA, which if granted would allow for an FDA approval decision (PDUFA date) in mid-2026. INOVIO is conducting ongoing market research with physicians, patients and payors to support its commercial readiness plans. Additionally, clinical and immunology data from a Phase 1/2 trial was published in the peer-reviewed scientific journal Nature Communications in February 2025 and longer-term follow up data was submitted to another peer-reviewed journal for publication. INOVIO has presented key efficacy, safety, immunological and durability data from the Phase 1/2 trial at a number of scientific conferences, including the following: National HPV Conference (April 15) World Vaccine Congress (April 21) Festival of Biologics (April 23) European Laryngological Society (ELS) Annual Congress (May 9) American Society of Gene and Cell Therapy (May 13) On May 14th INOVIO will also be presenting at the American Broncho-Esophagological Association Combined Otolaryngology Spring Meeting (ABEA/COSM), the largest US national meeting for otolaryngologists, the specialist physicians who treat the majority of RRP patients. Available abstracts are posted to INOVIO's website following presentations. DNA-Encoded Monoclonal Antibodies (DMAbs)In the first quarter, INOVIO and its collaborators announced top-line interim results from an ongoing Phase 1 proof-of-concept trial evaluating its DMAb technology. Additional data from this trial will be presented at the annual meeting of the American Society of Gene and Cell Therapy in May. The data is also anticipated to be published in a peer-reviewed journal. As previously announced, the interim results are currently available in preprint form on Research Square. In the trial, which used monoclonal antibodies against COVID-19 as proof-of-concept targets, 100% (24/24) of participants who reached week 72 maintained biologically relevant levels of DMAbs, confirming the durability of in vivo antibody production. Notably, no participant developed anti-drug antibodies, a common challenge observed in other gene-based delivery platforms, such as adeno-associated virus-mediated antibody expression. First Quarter 2025 Financial Results Research and Development (R&D) Expenses: R&D expenses for the three months ended March 31, 2025, decreased to $16.1 million from $20.9 million for the same period in 2024. The decrease was primarily the result of lower drug manufacturing and immunology expenses related to INO-3107, lower contract labor expenses and lower expensed inventory, partially offset by higher engineering professional and outside services related to our device development, among other variances. General and Administrative (G&A) Expenses: G&A expenses decreased to $9.0 million for the three months ended March 31, 2025 from $10.6 million for the same period in 2024. The decrease was primarily related to a decrease in legal expenses and employee and consultant stock-based compensation, among other variances. Total Operating Expenses: Total operating expenses decreased to $25.1 million for the three months ended March 31, 2025 from $31.5 million for the same period in 2024. Net Loss: Net loss for the three months ended March 31, 2025 decreased to $19.7 million, or $0.51 per basic and diluted share, from a net loss of $30.5 million, or $1.31 per basic and diluted share, for the three months ended March 31, 2024. Shares Outstanding: As of March 31, 2025, INOVIO had 36.7 million common shares outstanding and 51.3 million common shares outstanding on a fully diluted basis, after giving effect to the exercise, vesting, and conversion, as applicable, of its outstanding common stock warrants, including pre-funded warrants and stock options, restricted stock units and convertible preferred stock. Cash, Cash Equivalents and Short-term Investments: As of March 31, 2025, cash, cash equivalents and short-term investments were $68.4 million, compared to $94.1 million as of December 31, 2024. INOVIO's balance sheet and statement of operations are provided below. Additional information is included in INOVIO's quarterly report on Form 10-Q for the quarter ended March 31, 2025, which can be accessed at: Cash GuidanceINOVIO estimates its current cash, cash equivalents and short-term investments balances to support the company's operations into the first quarter of 2026. This projection includes an operational net cash burn estimate of approximately $22 million for the second quarter of 2025. These projections do not include any further capital-raising activities that INOVIO may undertake. Conference Call / Webcast InformationINOVIO's management will host a live conference call and webcast with slides at 4:30 p.m. ET today to discuss INOVIO's financial results and provide a general business update. The live webcast and replay may be accessed by visiting INOVIO's website at About INOVIO's DNA Medicines PlatformINOVIO's DNA medicines platform has two innovative components: precisely designed DNA plasmids, delivered by INOVIO's proprietary investigational medical device, CELLECTRA®. INOVIO uses proprietary technology to design its DNA plasmids, which are small circular DNA molecules that work like software the body's cells can download to produce specific proteins to target and fight disease. INOVIO's proprietary CELLECTRA® delivery devices are designed to optimally deliver its DNA medicines to the body's cells without requiring chemical adjuvants or lipid nanoparticles and without the risk of the anti-vector response historically seen with viral vector platforms. About INOVIOINOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit Forward-Looking StatementsThis press release contains certain forward-looking statements relating to our business, including the planned initiation and conduct of pre-clinical studies and clinical trials and the availability and timing of data from those studies and trials, the completion of the FDA-required device verification testing, the planned submission of a BLA in mid-2025 and request for priority review and goal of FDA's acceptance of the submission by the end of 2025, the potential commercial launch of INO-3107 if regulatory approval is obtained, the potential benefits of our product candidates, expectations regarding sufficiency of our cash resources into the first quarter of 2026 and expected cash burn for the second quarter of 2025. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials, product development programs and commercialization activities and outcomes, the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA medicines, our ability to support our pipeline of DNA medicine products, the ability of our collaborators to attain development and commercial milestones for products we license and product sales that will enable us to receive future payments and royalties, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by us or collaborators, including alternatives that may be more efficacious or cost effective than any therapy or treatment that we and our collaborators hope to develop, issues involving product liability, issues involving patents and whether they or licenses to them will provide us with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether we can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of our technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2024, our Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, and other filings we make from time to time with the Securities and Exchange Commission. There can be no assurance that any product candidate in our pipeline will be successfully developed, manufactured, or commercialized, that the results of clinical trials will be supportive of regulatory approvals required to market products, or that any of the forward-looking information provided herein will be proven accurate. Forward-looking statements speak only as of the date of this release, and we undertake no obligation to update or revise these statements, except as may be required by law. ContactsMedia: Jennie Willson, (267) 429-8567, communications@ Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, Inovio Pharmaceuticals, Inc. CONSOLIDATED BALANCE SHEETS March 31, 2025December 31, 2024(Unaudited) ASSETSCurrent assets:Cash and cash equivalents $39,915,447$65,813,297 Short-term investments 28,447,09728,300,232 Accounts receivable from affiliated entity 1,310,2371,199,056 Prepaid expenses and other current assets 2,221,6682,517,465 Total current assets 71,894,44997,830,050 Fixed assets, net 3,347,8243,659,818 Investments in affiliated entity 2,308,9751,613,844 Operating lease right-of-use assets 7,741,7578,113,840 Other assets 1,979,6541,979,654 Total assets $87,272,659$113,197,206 LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable and accrued expenses $12,919,788$16,200,013 Accounts payable and accrued expenses due to affiliated entity 469,6371,351,163 Accrued clinical trial expenses 1,819,2372,021,860 Common stock warrant liability 9,542,31613,255,188 Operating lease liability 2,575,9022,497,360 Total current liabilities 27,326,88035,325,584 Operating lease liability, net of current portion 8,695,0559,367,827 Total liabilities 36,021,93544,693,411 Stockholders' equity:Preferred stock —— Common stock 36,67436,099 Additional paid-in capital 1,801,789,3291,799,362,625 Accumulated deficit (1,749,913,959)(1,730,219,262) Accumulated other comprehensive loss (661,320)(675,667) Total Inovio Pharmaceuticals, Inc. stockholders' equity 51,250,72468,503,795 Total liabilities and stockholders' equity $87,272,659$113,197,206 Inovio Pharmaceuticals, Inc. CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended March 31,20252024 Revenues:Revenue from collaborative arrangements $65,343$— Operating expenses:Research and development 16,090,90220,913,790 General and administrative 9,024,97010,571,179 Total operating expenses 25,115,87231,484,969 Loss from operations (25,050,529)(31,484,969) Other income (expense):Interest income 808,0771,500,290 Interest expense —(177,833) Change in fair value of common stock warrant liability 3,712,872— Gain (loss) on investment in affiliated entity 695,131(126,018) Net unrealized gain on available-for-sale equity securities 140,234500,877 Other expense, net (482)(682,218) Net loss $(19,694,697)$(30,469,871) Net loss per share Basic and diluted $(0.51)$(1.31) Weighted average number of common shares used to compute net loss per share Basic and diluted 38,613,65323,291,512 View original content to download multimedia: SOURCE INOVIO Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-04-2025
- Politics
- Yahoo
New Mexico Attorney General calls to reinstate refugee resettlement program
NEW MEXICO (KRQE) — Leaders across the county, including the New Mexico Attorney General, are calling on the Trump administration to reinstate the refugee resettlement program. Story continues below Trending: ABQ family defies all odds after their fetus received a rare diagnosis Breaking: Pope Francis dies at 88 Crime: Repeat International District murder suspect facing new charges The RRP was initially federally funded through the US Department of Health and Human Services, but was suspended when President Trump took office in January. It helped refugees become self-sufficient by offering financial, medical and other services. 'We have been blessed in this country with great power and great resources,' New Mexico Attorney General Raúl Torrez said. 'And I think the mark of our greatness is how we use that power.' Torrez says he believes American people are very generous people, which is why they have such strong support for helping refugees. Last month, Torrez signed a letter to Secretary Marco Rubio demanding RRP be reinstated. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
